Replimune Group (NASDAQ:REPL) Given "Neutral" Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their neutral rating on shares of Replimune Group (NASDAQ:REPL - Free Report) in a research note published on Tuesday morning, Marketbeat Ratings reports. JPMorgan Chase & Co. currently has a $9.00 target price on the stock, down from their previous target price of $19.00.

Several other analysts also recently commented on the stock. Cantor Fitzgerald initiated coverage on shares of Replimune Group in a report on Friday, June 20th. They issued an "overweight" rating for the company. Wedbush reissued a "neutral" rating and issued a $4.00 target price (down previously from $19.00) on shares of Replimune Group in a report on Tuesday. HC Wainwright reissued a "buy" rating and set a $22.00 target price on shares of Replimune Group in a research report on Thursday, July 3rd. Finally, Piper Sandler reissued a "neutral" rating and set a $3.00 target price on shares of Replimune Group in a research report on Tuesday. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Replimune Group presently has a consensus rating of "Moderate Buy" and an average target price of $11.38.

Replimune Group Price Performance

Shares of NASDAQ:REPL traded down $9.51 during trading on Tuesday, reaching $2.81. The stock had a trading volume of 86,521,297 shares, compared to its average volume of 1,307,645. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.95 and a current ratio of 7.95. The stock has a market cap of $216.62 million, a PE ratio of -0.92 and a beta of 0.61. The business has a fifty day moving average price of $9.62 and a 200-day moving average price of $10.46. Replimune Group has a 1-year low of $2.68 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period last year, the company posted ($0.25) EPS. On average, equities analysts forecast that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, Director Philip Astley-Sparke sold 32,279 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the sale, the director owned 1,405,071 shares of the company's stock, valued at approximately $11,324,872.26. This trade represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sushil Patel sold 25,105 shares of Replimune Group stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $202,346.30. Following the completion of the sale, the chief executive officer directly owned 343,576 shares in the company, valued at $2,769,222.56. This represents a 6.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 over the last three months. 8.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its position in Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock valued at $6,729,000 after acquiring an additional 119,145 shares during the period. Optimize Financial Inc bought a new position in Replimune Group in the first quarter worth $140,000. Exome Asset Management LLC grew its holdings in shares of Replimune Group by 438.6% in the 1st quarter. Exome Asset Management LLC now owns 294,846 shares of the company's stock worth $2,875,000 after purchasing an additional 240,108 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Replimune Group during the first quarter worth $343,000. Finally, Parkman Healthcare Partners LLC raised its holdings in Replimune Group by 9.3% in the first quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company's stock worth $9,266,000 after purchasing an additional 80,640 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.